News from intermune, inc

Jul 17, 2014, 12:38 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Receives FDA Breakthough Therapy Designation For Pirfenidone, An Investigational Treatment For IPF

 InterMune, Inc. (Nasdaq: ITMN) today announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. Food and Drug...

May 27, 2014, 07:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF

InterMune, Inc. (Nasdaq: ITMN) today announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug...

May 20, 2014, 17:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Announces Additional Pirfenidone Data in Idiopathic Pulmonary Fibrosis

 InterMune, Inc. (NASDAQ: ITMN) today announced that results of analyses of pooled data from the ASCEND trial and the two previous Phase 3...

May 18, 2014, 17:02 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis Presented at American Thoracic Society (ATS) and Published in New England Journal of Medicine

InterMune, Inc. (NASDAQ: ITMN) today reported that results from the Phase 3 ASCEND study evaluating pirfenidone in patients with idiopathic...

May 16, 2014, 08:00 ET

InterMune Announces Expanded Access Program for Pirfenidone to Treat Idiopathic Pulmonary Fibrosis (IPF) in the United States

 InterMune, Inc. (NASDAQ: ITMN) today announced it will provide compassionate use of pirfenidone through a multi-center Expanded Access...

May 12, 2014, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Announces Upcoming Data Presentations at 2014 American Thoracic Society Meeting

 InterMune, Inc. (NASDAQ: ITMN) today announced that several investigational molecules and data from studies of pirfenidone will be presented...

May 01, 2014, 16:01 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Reports First Quarter 2014 Financial Results, Clinical Development and Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the first quarter ended March 31, 2014.  The company also...

Apr 23, 2014, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune To Release First Quarter Financial Results On May 1

 InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2014 financial results at the close of the U.S. markets...

Mar 13, 2014, 19:20 ET

InterMune Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock

InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 7,500,000 shares of its common stock at a price to the public of $32.75...

Mar 12, 2014, 16:02 ET

InterMune Announces Proposed Public Offering of Common Stock

 InterMune, Inc. (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 7,500,000 shares of its common...

Feb 28, 2014, 07:00 ET
Logo InterMune

InterMune® apoya la primera Carta del Paciente europeo sobre la fibrosis pulmonar idiopática

InterMune® anuncia su apoyo a la primera Carta del Paciente europeo sobre la fibrosis pulmonar idiopática (FPI) Para conmemorar el...

Feb 28, 2014, 01:00 ET
Logo InterMune

InterMune® annonce son soutien à la création de la première Charte européenne des patients atteints de fibrose pulmonaire idiopathique (FPI)

A l'occasion de la Journée internationale des maladies rares, InterMune annonce son soutien au développement d'une Charte...

Feb 25, 2014, 07:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)

 InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with...

Jan 09, 2014, 07:30 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Reports Preliminary Fourth Quarter 2013 Esbriet® (pirfenidone) Revenue and Recent Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced unaudited revenue for the fourth quarter and year ended December 31, 2013.  The company...

Jan 06, 2014, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune to Present at J. P. Morgan Healthcare Conference

 InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at...

Dec 10, 2013, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Announces Support of The Pulmonary Fibrosis Foundation Care Center Network and Patient Registry Initiative

InterMune (NASDAQ: ITMN) today announced its support of the Pulmonary Fibrosis Foundation, a leading patient advocacy organization dedicated...

Nov 05, 2013, 21:25 ET

InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock

InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 6,500,000 shares of its common stock at a price to the public of $13.00...

Nov 04, 2013, 16:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Announces Proposed Public Offering of Common Stock

InterMune, Inc. (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 6,500,000 shares of its common stock...

Oct 30, 2013, 16:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Reports Third Quarter 2013 Financial Results And Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2013, and...

Oct 23, 2013, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune To Release Third Quarter Financial Results On October 30

InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its third quarter 2013 financial results at the close of the U.S. markets on...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
ReportBuyer
Investor-Edge